Data on EFAPROXYN(TM) and RH1 to be Presented at Upcoming Scientific Conferences
08 11월 2005 - 10:02PM
PR Newswire (US)
WESTMINSTER, Colo., Nov. 8 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH) today announced that data
evaluating the Company's product candidates EFAPROXYN (efaproxiral)
and RH1 have been accepted for presentation at the following
scientific conferences: * AACR-NCI-EORTC International Conference
on Molecular Targets and Cancer Therapeutics: Sarah Danson, M.D.,
Department of Medical Oncology, Christie Hospital, is scheduled to
report updated clinical and PK/PD data from an on-going Phase 1
study of RH1 in patients with advanced solid tumors in a poster
presentation titled "Phase 1 Pharmacokinetic (PD) trial of the
bioreductive drug RH1" on Thursday, November 17. * San Antonio
Breast Cancer Symposium: Charles Scott, Ph.D., CBS Squared, is
scheduled to present a quality adjusted survival analysis of the
Phase 3 REACH study of EFAPROXYN in patients with brain metastases
in a poster presentation titled "Improved survival, quality of life
and quality-adjusted survival in breast cancer patients treated
with efaproxiral + whole brain radiation therapy for brain
metastases" on Saturday, December 10. Copies of the abstracts will
be available on the AACR (http://www.aacr.org/) and SABCS
(http://www.sabcs.org/) web sites. About Allos Therapeutics, Inc.
Allos Therapeutics, Inc. (NASDAQ:ALTH) is a biopharmaceutical
company focused on developing and commercializing innovative small
molecule therapeutics for the treatment of cancer. The Company's
lead product candidate, EFAPROXYN(TM) (efaproxiral), is a synthetic
small molecule designed to sensitize hypoxic, or oxygen-deprived,
tumor tissue during radiation therapy. EFAPROXYN is currently being
evaluated as an adjunct to whole brain radiation therapy in a
pivotal Phase 3 trial in women with brain metastases originating
from breast cancer. The Company's other product candidates are: PDX
(pralatrexate), a small molecule chemotherapeutic agent (DHFR
inhibitor) currently under investigation as both a single agent and
in combination therapy regimens in patients with non-small cell
lung cancer and Non-Hodgkin's lymphoma; and RH1, a small molecule
chemotherapeutic agent bioactivated by the enzyme DT-diaphorase
currently under evaluation in patients with advanced solid tumors.
For more information, please visit the Company's web site at:
http://www.allos.com/. Safe Harbor Statement The anticipated
presentations will contain forward-looking statements that involve
significant risks and uncertainties, including those to be
discussed in the presentation and others that can be found in the
"Risk Factors" section of the Company's Form 10-K for the year
ended December 31, 2004 and in the Company's periodic reports on
Form 10-Q and Form 8-K. The Company does not undertake any
obligation to update any forward-looking statements contained in
the anticipated presentation as a result of new information, future
events or otherwise. The Company cautions investors not to place
undue reliance on the forward-looking statements contained in the
presentation. No forward-looking statement can be guaranteed and
actual events and results may differ materially from those
projected. DATASOURCE: Allos Therapeutics, Inc. CONTACT: Jennifer
Neiman, Manager, Corporate Communications of Allos Therapeutics,
+1-720-540-5227, Web site: http://www.sabcs.org/ Web site:
http://www.aacr.org/ Web site: http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Allos Therapeutics (MM) News Articles